Supplementary Information

Enhanced Immunocompatibility of Ligand-targeted Liposomes by Attenuating Natural IgM Absorption

Guan and Shen et al

Supplementary Figures



Supplementary Figure 1. The uptake of sLip, ^LCDX-sLip and ^DCDX-sLip by RAW264.7 cells. (a) Microscopic observation and (b, c) quantitative analysis of phagocytosis of sLip, ^LCDX-sLip and ^DCDX-sLip with or without 2 h pre-incubation with 200 μ M free ^DCDX peptide. Scale bar = 20 μ m. n = 3, Data are means \pm s.d.



Supplementary Figure 2. Cytotoxicity of free D8 peptide and D8-sLip. (a) Cytotoxicity of free D8 peptide against bEnd.3 and AML12 cells. sLip and D8-sLip against (b) AML12 and (c) bEnd.3 cells after 48 h incubation at 37 °C. Data are means \pm s.d. (n = 3).



Supplementary Figure 3. 1H-NMR spectra of mal-PEG3400-DSPE and peptide-PEG3400-DSPE. The characteristic peak of maleimide at 6.8 ppm was circled.

Supplementary Tables

Supplementary Table 1. Area under the curve $(AUC_{0.24})$ of liposomes (50 mg HSPC per kg of mouse) with or without pre-dose of blank liposomes (5 mg HSPC per kg of mouse, no DiI loading) in BALB/c mice. n=3, data are means \pm s.d.

	$AUC_{0-24} \ (\mu g \cdot h \ mL^{-1})$		
	Without pre-dose	With pre-dose	
sLip	584.2 ± 6.8	350.3 ± 10.7	
^L CDX-sLip	164.8 ± 10.1	8.7 ± 4.7	
^D CDX-sLip	18.3 ± 2.4	7.3 ± 0.6	
D8-sLip	286.8 ± 21.5	112.7 ± 13.9	

Supplementary Table 2. Characterization of sLip, ^LCDX-sLip and ^DCDX-sLip with or without pre-incubation with serum at 37°C for 1 h, n = 3, data are means \pm s.d.

	Without serum			With serum		
_	Size (nm)	PDI	Zeta (mV)	Size (nm)	PDI	Zeta (mV)
sLip	138.9±0.72	0.059 ± 0.02	-48.33±1.97	120.8 ± 0.98	0.286 ± 0.01	-19.23±1.57
^L CDX-sLip	138.8±0.14	0.086 ± 0.02	-30.87 ± 0.95	123.4±2.82	0.246 ± 0.02	-14.63±1.28
^D CDX-sLip	136.4±2.48	0.057 ± 0.01	-31.45±0.46	118.8±1.56	0.301 ± 0.02	-15.46±2.02

Supplementary Table 3. Peptide sequences.

Peptide	Sequence	Length (AA)
^L CDX	FKESWREARGTRIERG	16
^D CDX	$G^{D}R^{D}E^{D}I^{D}R^{D}TG^{D}R^{D}A^{D}E^{D}R^{D}W^{D}S^{D}E^{D}K^{D}F$	16
^D CDX-1	$G^{D}R^{D}A^{D}I^{D}R^{D}TG^{D}R^{D}A^{D}E^{D}R^{D}W^{D}S^{D}A^{D}K^{D}F$	16
^D CDX-2	$G^{D}A^{D}E^{D}I^{D}R^{D}TG^{D}R^{D}A^{D}E^{D}R^{D}W^{D}S^{D}E^{D}A^{D}F$	16
^D CDX-S8	${}^{\mathrm{D}}\mathrm{R}^{\mathrm{D}}\mathrm{T}\mathrm{G}^{\mathrm{D}}\mathrm{R}^{\mathrm{D}}\mathrm{A}^{\mathrm{D}}\mathrm{E}^{\mathrm{D}}\mathrm{R}^{\mathrm{D}}\mathrm{W}$	8
ANG	TFFYGGSRGKRNNFKTEEY	19
D8	^D RTG ^D R ^D A ^D RE ^D W	8

Supplementary Table 4. Characterization of different liposomes shown in the table with or without pre-incubation of serum at 37°C for 1 h. Size and zeta potential were all measured by Malvern laser particle size analyzer. n = 3, data are means \pm s.d.

.	Without serum			With serum		
Liposomes -	Size (nm)	PDI	Zeta-potenti al (mV)	Size (nm)	PDI	Zeta-potenti al (mV)
D8-sLip	135.7 ± 1.79	0.017±0.02	-38.5 ± 1.73	128.6±1.28	0.302±0.01	-17.2 ± 1.02
DOTAP-sLip	157.8±0.57	0.104±0.02	59.5±0.95	122.5±0.56	0.247±0.02	-16.9±0.86
^D CDX-1-sLip	141.6 ± 0.46	0.116 ± 0.04	17.5 ± 2.96	125.8±0.58	0.267±0.01	-20.4±1.31
^D CDX-2-sLip	136.9 ± 1.34	0.163±0.02	-38.9±0.89	99.74±0.86	0.222±0.03	-19.4±0.97
Angiopep-2-sLip	128.1±1.90	0.091±0.02	-32.6±1.69	246.9±1.97	0.683±0.02	-17.1±0.58
^D CDX-S8-sLip	136.5 ± 2.19	0.064±0.01	-37.9±0.20	124.6±1.86	0.158±0.03	-16.1±0.75

Peptide sequence	Predicted ΔG [kcal mol ⁻¹]
$G^{D}R^{D}E^{D}I^{D}R^{D}TG^{D}R^{D}A^{D}E^{D}R^{D}W^{D}S^{D}E^{D}K^{D}F$	-10.11
${}^{\mathrm{D}}\mathbf{R}^{\mathrm{D}}\mathbf{T}\mathbf{G}^{\mathrm{D}}\mathbf{R}^{\mathrm{D}}\mathbf{A}^{\mathrm{D}}\mathbf{E}^{\mathrm{D}}\mathbf{R}^{\mathrm{D}}\mathbf{W}$	-10.47
^D R ^D TG ^D R ^D A ^D RE ^D W	-11.06
^D RTG ^D R ^D A ^D RE ^D W	-11.48

Supplementary Table 5. Predicted free energies of binding of the peptides with α 7 nAChR